(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Tilray, Novo Nordisk A/S, and Sabre Corporation.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Tilray (TLRY) | 3.03 | 36.26% | 2023-08-08 14:46:03 |
| 2 | Novo Nordisk A/S (NVO) | 188.86 | 17.04% | 2023-08-08 14:50:34 |
| 3 | Sabre Corporation (SABR) | 5.36 | 15.38% | 2023-08-08 14:57:29 |
| 4 | Eli Lilly and Company (LLY) | 517.52 | 13.97% | 2023-08-08 13:42:18 |
| 5 | Perma-Fix Environmental Services (PESI) | 11.12 | 13.47% | 2023-08-07 19:14:07 |
| 6 | Viking Therapeutics (VKTX) | 14.33 | 12.75% | 2023-08-08 14:46:24 |
| 7 | Schmitt Industries (SMIT) | 0.02 | 10.6% | 2023-08-08 15:49:09 |
| 8 | Amicus Therapeutics (FOLD) | 13.80 | 10.01% | 2023-08-08 14:55:09 |
| 9 | SNDL Inc. (SNDL) | 1.64 | 9.73% | 2023-08-08 14:45:47 |
| 10 | DISH Network (DISH) | 8.35 | 9.29% | 2023-08-08 14:39:09 |
The three biggest losers today are SeaChange International, Everbridge, and Internationa Flavors & Fragrances.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | SeaChange International (SEAC) | 4.78 | -39.26% | 2023-08-08 11:23:07 |
| 2 | Everbridge (EVBG) | 22.65 | -22.29% | 2023-08-08 13:36:49 |
| 3 | Internationa Flavors & Fragrances (IFF) | 64.69 | -19.48% | 2023-08-08 13:41:34 |
| 4 | Arcturus Therapeutics (ARCT) | 25.70 | -19.31% | 2023-08-08 14:58:47 |
| 5 | Aspen Group (ASPU) | 0.15 | -18.72% | 2023-08-08 13:14:03 |
| 6 | Ringcentral (RNG) | 32.03 | -17.83% | 2023-08-08 13:44:30 |
| 7 | FibroGen (FGEN) | 1.46 | -17.8% | 2023-08-08 14:24:46 |
| 8 | Datadog (DDOG) | 88.14 | -17.09% | 2023-08-08 14:59:23 |
| 9 | Redhill Biopharma Ltd. (RDHL) | 0.91 | -14.95% | 2023-08-08 05:08:07 |
| 10 | Five9 (FIVN) | 69.92 | -14.38% | 2023-08-08 14:54:59 |
Winners today
1. Tilray (TLRY) – 36.26%
Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
NASDAQ ended the session with Tilray jumping 36.26% to $3.03 on Tuesday while NASDAQ dropped 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Tilray has a trailing twelve months EPS of $-3.1.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 53.8% and 54.5%, respectively.
Sales Growth
Tilray’s sales growth for the current quarter is 13.4%.
Volume
Today’s last reported volume for Tilray is 118262000 which is 496.84% above its average volume of 19814500.
Previous days news about Tilray
- : canadian pot company tilray is buying 8 beer and beverage brands from AB inbev. According to MarketWatch on Monday, 7 August, "Canadian cannabis producer Tilray Brands Inc. on Monday said it had agreed to buy eight beer and drink brands from Anheuser-Busch InBev – including Shock Top, Redhook Brewery and Widmer Brothers Brewing. ", "The deal follows other efforts by Tilray to expand into alcohol, amid heavy competition in Canada’s legal cannabis industry and stalled federal reform in the U.S. Shares rose 2.7% after hours on Monday."
- Canadian pot company tilray is buying 8 beer and beverage brands from AB inbev. According to MarketWatch on Monday, 7 August, "Canadian cannabis producer Tilray Brands Inc. on Monday said it had agreed to buy eight beer and drink brands from Anheuser-Busch InBev – including Shock Top, Redhook Brewery and Widmer Brothers Brewing. ", "The deal follows other efforts by Tilray to expand into alcohol, amid heavy competition in Canada’s legal cannabis industry and stalled federal reform in the U.S. Shares rose 2.7% after hours on Monday."
More news about Tilray.
2. Novo Nordisk A/S (NVO) – 17.04%
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NYSE ended the session with Novo Nordisk A/S rising 17.04% to $188.86 on Tuesday, after two consecutive sessions in a row of gains. NYSE slid 0.2% to $16,176.35, following the last session’s upward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $4.06.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 46.52. Meaning, the purchaser of the share is investing $46.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 83.5%.
More news about Novo Nordisk A/S.
3. Sabre Corporation (SABR) – 15.38%
Sabre Corporation, through its subsidiaries, provides software and technology solutions for the travel industry worldwide. It operates in two segments, Travel Solutions and Hospitality Solutions. The Travel Solutions segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments. This segment also provides a portfolio of software technology products and solutions through software-as-a-service (SaaS) and hosted delivery models to airlines and other travel suppliers. Its products include reservation systems for carriers, commercial and operations products, agency solutions, and data-driven intelligence solutions. The Hospitality Solutions segment provides software and solutions to hoteliers through SaaS and hosted delivery models. Sabre Corporation was incorporated in 2006 and is headquartered in Southlake, Texas.
NASDAQ ended the session with Sabre Corporation jumping 15.38% to $5.36 on Tuesday while NASDAQ dropped 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Sabre Corporation has a trailing twelve months EPS of $-1.82.
Yearly Top and Bottom Value
Sabre Corporation’s stock is valued at $5.36 at 17:32 EST, way under its 52-week high of $8.31 and way higher than its 52-week low of $2.99.
More news about Sabre Corporation.
4. Eli Lilly and Company (LLY) – 13.97%
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
NYSE ended the session with Eli Lilly and Company jumping 13.97% to $517.52 on Tuesday, after two consecutive sessions in a row of gains. NYSE dropped 0.2% to $16,176.35, following the last session’s upward trend on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $6.3.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 82.15. Meaning, the purchaser of the share is investing $82.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 54.79%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 59.2% and 17.7%, respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Eli Lilly and Company’s stock is considered to be overbought (>=80).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Eli Lilly and Company’s EBITDA is 212.65.
Volume
Today’s last reported volume for Eli Lilly and Company is 12165200 which is 364.21% above its average volume of 2620570.
More news about Eli Lilly and Company.
5. Perma-Fix Environmental Services (PESI) – 13.47%
Perma-Fix Environmental Services, Inc., through its subsidiaries, operates as an environmental and technology know-how company in the United States. It operates in three segments: Treatment, Services, and Medical. The Treatment segment offers nuclear, low-level radioactive, mixed waste, hazardous and non-hazardous waste treatment, and processing and disposal services through treatment and storage facilities. This segment is also involved in the research and development activities to identify, develop, and implement waste processing techniques for problematic waste streams. The Services segment provides technical services, including professional radiological measurement and site survey of government and commercial installations; integrated occupational safety and health services; and consulting, engineering, project and waste management, environmental, decontamination and decommissioning (D&D) field, technical, on-site waste management services, and management personnel and services. This segment also offers nuclear services, including technology-based services comprising engineering, D&D, specialty, construction, logistics, transportation, processing, and disposal; offers remediation of nuclear licensed and federal facilities, as well as cleanup of nuclear legacy sites; and owns an equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources health physics, industrial hygiene, and customized nuclear, environmental, and occupational safety and health instrumentation. The Medical segment is involved in the research and development of medical isotope production technology. The company provides its services to research institutions, commercial companies, public utilities, and governmental agencies through direct sales to customers or through intermediaries. Perma-Fix Environmental Services, Inc. was incorporated in 1990 and is based in Atlanta, Georgia.
NASDAQ ended the session with Perma-Fix Environmental Services rising 13.47% to $11.12 on Tuesday, after three sequential sessions in a row of gains. NASDAQ slid 0.79% to $13,884.32, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, Perma-Fix Environmental Services has a trailing twelve months EPS of $-0.16.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.32%.
Volatility
Perma-Fix Environmental Services’s last week, last month’s, and last quarter’s current intraday variation average was 3.72%, 0.24%, and 3.14%.
Perma-Fix Environmental Services’s highest amplitude of average volatility was 6.79% (last week), 3.25% (last month), and 3.14% (last quarter).
Moving Average
Perma-Fix Environmental Services’s worth is above its 50-day moving average of $10.52 and way above its 200-day moving average of $7.40.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.7%, now sitting on 80.37M for the twelve trailing months.
More news about Perma-Fix Environmental Services.
6. Viking Therapeutics (VKTX) – 12.75%
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
NASDAQ ended the session with Viking Therapeutics rising 12.75% to $14.33 on Tuesday while NASDAQ slid 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.94.
Moving Average
Viking Therapeutics’s worth is way under its 50-day moving average of $19.14 and way above its 200-day moving average of $12.46.
More news about Viking Therapeutics.
7. Schmitt Industries (SMIT) – 10.6%
Schmitt Industries, Inc., together with its subsidiaries, designs, manufactures, and sells test and measurement products worldwide. The company's Balancer segment offers computer-controlled vibration detection, balancing, and process control systems. Its products comprise SB-5500, an optional acoustic emission monitoring system (AEMS) control card to monitor the AE signals generated on the grinding machine; process control cards to provide enhanced control of the grinding process; SB-2000, a compact manual balancing system; and AE-1000, an AE control platform, which reduces air machine grinding time under the Schmitt Dynamic Balance System brand name. This segment sells its products to end user operators, as well as manufacturers of grinding machines for automotive, industrial, aerospace, and medical industries through independent manufacturers' representatives and distributors. Its Measurement segment provides laser and confocal chromatic white light sensors for distance, measurement, and dimensional sizing products under the Acuity brand name for various application, including manufacturing, lumber production, steel casting, glass and paper production, medical imaging, crane control and micron-level part, and surface inspection; and ultrasonic measurement products that measure the levels of liquid tanks and transmit that data through satellite to a secure Website for display, as well as remote tank monitoring products under the Xact brand name. Schmitt Industries, Inc. was founded in 1984 and is based in Portland, Oregon.
NASDAQ ended the session with Schmitt Industries rising 10.6% to $0.02 on Tuesday, following the last session’s downward trend. NASDAQ fell 0.79% to $13,884.32, following the last session’s upward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, Schmitt Industries has a trailing twelve months EPS of $-1.05.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -169.56%.
Volume
Today’s last reported volume for Schmitt Industries is 12351 which is 1386.28% above its average volume of 831.
More news about Schmitt Industries.
8. Amicus Therapeutics (FOLD) – 10.01%
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
NASDAQ ended the session with Amicus Therapeutics jumping 10.01% to $13.80 on Tuesday while NASDAQ slid 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Amicus Therapeutics has a trailing twelve months EPS of $-0.68.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -119.72%.
Volatility
Amicus Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.71%, a positive 0.30%, and a positive 1.75%.
Amicus Therapeutics’s highest amplitude of average volatility was 2.27% (last week), 1.67% (last month), and 1.75% (last quarter).
Volume
Today’s last reported volume for Amicus Therapeutics is 4007390 which is 47.41% above its average volume of 2718480.
Moving Average
Amicus Therapeutics’s value is way above its 50-day moving average of $12.50 and way above its 200-day moving average of $11.96.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Amicus Therapeutics’s EBITDA is -82.27.
Previous days news about Amicus Therapeutics
- Why earnings season could be great for amicus therapeutics (fold). According to Zacks on Monday, 7 August, "That is because Amicus Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. "
More news about Amicus Therapeutics.
9. SNDL Inc. (SNDL) – 9.73%
SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
NASDAQ ended the session with SNDL Inc. jumping 9.73% to $1.64 on Tuesday, after two sequential sessions in a row of losses. NASDAQ slid 0.79% to $13,884.32, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, SNDL Inc. has a trailing twelve months EPS of $-1.03.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.6%.
More news about SNDL Inc..
10. DISH Network (DISH) – 9.29%
DISH Network Corporation, together with its subsidiaries, provides pay-TV services in the United States. The company operates in two segments, Pay-TV and Wireless. It offers video services under the DISH TV brand; and programming packages that include programming through national broadcast networks, local broadcast networks, and national and regional cable networks, as well as regional and specialty sports channels, premium movie channels, and Latino and international programming packages. The company also provides access to movies and television shows through TV or Internet-connected devices; and dishanywhere.com and mobile applications on Internet-connected devices to view authorized content, search program listings, and remotely control certain features of their DVRs. In addition, it offers Sling TV services, including Sling domestic, Sling International, Sling Latino, Sling Orange, and Sling Blue services that require an internet connection and are available on streaming-capable devices, such as streaming media devices, TVs, tablets, computers, game consoles, and phones, as well as market SLING TV services to consumers who do not subscribe to traditional satellite and cable pay-TV services. Further, the company provides wireless subscribers consumer plans with no annual service contracts, as well as monthly service plans, including high-speed data and unlimited talk and text. The company offers receiver systems and programming through direct sales channels, as well as independent third parties, such as small retailers, direct marketing groups, local and regional consumer electronics stores, retailers, and telecommunications companies. DISH Network Corporation was founded in 1980 and is headquartered in Englewood, Colorado.
NASDAQ ended the session with DISH Network jumping 9.29% to $8.35 on Tuesday while NASDAQ slid 0.79% to $13,884.32.
Investigation alert: the schall law firm announces it is investigating claims against DISH network corporation and encourages investors with losses to contact the firmThe Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DISH Network Corporation (Dish or the Company) (NASDAQ: DISH) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company’s agreement to combine with EchoStar Corporation (EchoStar) in an all-stock merger.
Earnings Per Share
As for profitability, DISH Network has a trailing twelve months EPS of $3.07.
PE Ratio
DISH Network has a trailing twelve months price to earnings ratio of 2.72. Meaning, the purchaser of the share is investing $2.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.36%.
Yearly Top and Bottom Value
DISH Network’s stock is valued at $8.35 at 17:32 EST, way below its 52-week high of $20.35 and way higher than its 52-week low of $5.83.
Moving Average
DISH Network’s value is way above its 50-day moving average of $6.83 and way under its 200-day moving average of $10.99.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 64.6% and a negative 78.5%, respectively.
Sales Growth
DISH Network’s sales growth is negative 7.3% for the present quarter and negative 6.9% for the next.
More news about DISH Network.
Losers Today
1. SeaChange International (SEAC) – -39.26%
SeaChange International, Inc. provides multiscreen, advertising, and premium over the top (OTT) video products and services that facilitate the aggregation, licensing, management, and distribution of video and advertising content worldwide. The company offers video products, including video back-office, a software platform that enables content and service providers to manage, monetize and deliver a seamless viewing experience to subscribers across televisions, personal computers (PCs), tablets, smart phones, and other IP-enabled devices; and media asset management software, which is used to receive, manage and publish video content for viewing on televisions, tablets, PCs and other consumer devices. It also provides an advertising platform to maximize advertising revenue across multiscreen, broadcast, on-demand, and OTT viewing. In addition, the company offers client application, a multiscreen user experience product that empower service providers and content owners to optimize live and on-demand video consumption on multiscreen and OTT services. Further, it provides professional, and maintenance and technical support services, as well as managed services. The company sells and markets its products and services through a direct sales process, as well as to systems integrators and value-added resellers. It serves cable system operators, telecommunications companies, and satellite operators, as well as broadcasters and other content providers. The company was incorporated in 1993 and is headquartered in Boston, Massachusetts.
NASDAQ ended the session with SeaChange International dropping 39.26% to $4.78 on Tuesday while NASDAQ dropped 0.79% to $13,884.32.
Earnings Per Share
As for profitability, SeaChange International has a trailing twelve months EPS of $-3.69.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.07%.
Yearly Top and Bottom Value
SeaChange International’s stock is valued at $4.78 at 17:32 EST, way below its 52-week high of $12.20 and higher than its 52-week low of $4.59.
Moving Average
SeaChange International’s worth is way below its 50-day moving average of $8.24 and way below its 200-day moving average of $8.69.
More news about SeaChange International.
2. Everbridge (EVBG) – -22.29%
Everbridge, Inc. operates as a software company that enables customers to anticipate, mitigate, respond to, and recover from critical events in North America and internationally. The company offers Critical Event Management, a SaaS based platform, which offers various software applications for organizations for safeguarding business operations, people resilience, digital operations, smart security, and public safety. The Company's enterprise applications include Mass Notification, Safety Connection, IT Alerting, Visual Command Center, Public Warning, Community Engagement, Risk Center, Crisis Management, CareConverge, Control Center, 911 Connect, Travel Risk Management, SnapComms, and E911 for automating various critical event management processes. It serves enterprises, small businesses, non-profit organizations, educational institutions, and government agencies in technology, energy, financial services, healthcare and life sciences, manufacturing, media and entertainment, retail, higher education, and professional services industries. The company was formerly known as 3n Global, Inc. and changed its name to Everbridge, Inc. in April 2009. The company was founded in 2002 and is based in Burlington, Massachusetts.
NASDAQ ended the session with Everbridge sliding 22.29% to $22.65 on Tuesday while NASDAQ fell 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Everbridge has a trailing twelve months EPS of $-1.57.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.9%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Everbridge’s EBITDA is 981.62.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Everbridge’s stock is considered to be oversold (<=20).
Moving Average
Everbridge’s worth is way below its 50-day moving average of $27.18 and way below its 200-day moving average of $29.76.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 800% and 59.3%, respectively.
More news about Everbridge.
3. Internationa Flavors & Fragrances (IFF) – -19.48%
International Flavors & Fragrances Inc., together with its subsidiaries, manufactures and sells cosmetic active and natural health ingredients for use in various consumer products in Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. It operates through four segments: Nourish, Scent, Health & Biosciences, and Pharma Solutions. The Nourish segment offers natural and plant-based specialty food ingredients, such as flavor compounds; savory products that includes soups, sauces, meat, fish, poultry, snacks, etc.; beverages, such as juice drinks, carbonated or flavored beverages, spirits, etc.; sweets that includes bakery products, candy, cereal, chewing gum, etc.; and dairy products, such as yogurt, ice cream, cheese, etc. It also provides natural food protection ingredients consist of natural antioxidants and anti-microbials. Its Scent segment provides fragrance compounds, which include fine fragrances comprising perfumes and colognes, as well as consumer fragrances; fragrance ingredients comprising synthetic and natural ingredients that could be combined with other materials to create fragrance and consumer compounds; and cosmetic active ingredients consisting of active and functional ingredients, and delivery systems to support its customers' cosmetic and personal care product lines. The Health & Biosciences segment develops and produces enzymes, food cultures, probiotics, and specialty ingredients for food and non-food applications. Its Pharma Solutions segment produces and sells cellulosics and seaweed-based pharma excipients. The company sells its products primarily to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, dietary supplements, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products. International Flavors & Fragrances Inc. was founded in 1833 and is headquartered in New York, New York.
NYSE ended the session with Internationa Flavors & Fragrances dropping 19.48% to $64.69 on Tuesday while NYSE slid 0.2% to $16,176.35.
Earnings Per Share
As for profitability, Internationa Flavors & Fragrances has a trailing twelve months EPS of $-8.32.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.89%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 6.2%, now sitting on 12.24B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Internationa Flavors & Fragrances’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for Internationa Flavors & Fragrances is 8337150 which is 268.14% above its average volume of 2264640.
More news about Internationa Flavors & Fragrances.
4. Arcturus Therapeutics (ARCT) – -19.31%
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
NASDAQ ended the session with Arcturus Therapeutics falling 19.31% to $25.70 on Tuesday, after five sequential sessions in a row of losses. NASDAQ fell 0.79% to $13,884.32, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $4.25.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 6.05. Meaning, the purchaser of the share is investing $6.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.3%.
Yearly Top and Bottom Value
Arcturus Therapeutics’s stock is valued at $25.70 at 17:32 EST, way under its 52-week high of $37.75 and way above its 52-week low of $13.02.
Moving Average
Arcturus Therapeutics’s value is way under its 50-day moving average of $29.21 and way higher than its 200-day moving average of $22.16.
More news about Arcturus Therapeutics.
5. Aspen Group (ASPU) – -18.72%
Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.
NASDAQ ended the session with Aspen Group falling 18.72% to $0.15 on Tuesday while NASDAQ dropped 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Aspen Group has a trailing twelve months EPS of $-0.36.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.
More news about Aspen Group.
6. Ringcentral (RNG) – -17.83%
RingCentral, Inc. provides cloud communications, video meetings, collaboration, and contact center software-as-a-service solutions worldwide. The company's products include RingCentral Message Video Phone (MVP) that provides a unified experience for communication and collaboration across multiple modes, including HD voice, video, SMS, messaging and collaboration, conferencing, online meetings, and fax; RingCentral Contact Center, a collaborative contact center solution that delivers AI powered omni-channel and workforce engagement solution with integrated RingCentral MVP; and RingCentral Engage Digital, a digital customer engagement platform that allows enterprises to interact with their customers. The company's products also comprise RingCentral Engage Voice, a cloud-based outbound/blended customer engagement platform for midsize and enterprise companies; RingCentral Video, a video meeting service which includes the company's RCV video and team messaging capabilities and offers video and audio conferencing, file sharing, contact, task, and calendar management. In addition, it offers RingCentral professional services. The company serves a range of industries, including financial services, education, healthcare, legal services, real estate, retail, technology, insurance, construction, hospitality, and state and local government, as well as others. It sells its products through a network of direct sales representatives, as well as sales agents, resellers, and channel partners. The company was incorporated in 1999 and is headquartered in Belmont, California.
NYSE ended the session with Ringcentral sliding 17.83% to $32.03 on Tuesday, following the last session’s upward trend. NYSE fell 0.2% to $16,176.35, following the last session’s upward trend on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, Ringcentral has a trailing twelve months EPS of $-7.87.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 66.7% and 49.1%, respectively.
More news about Ringcentral.
7. FibroGen (FGEN) – -17.8%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen falling 17.8% to $1.46 on Tuesday while NASDAQ dropped 0.79% to $13,884.32.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.84.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -411.93%.
Previous days news about FibroGen
- Fibrogen (fgen) reports Q2 loss, tops revenue estimates. According to Zacks on Monday, 7 August, "While FibroGen has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about FibroGen.
8. Datadog (DDOG) – -17.09%
Datadog, Inc. operates an observability and security platform for cloud applications in North America and internationally. The company's products include infrastructure and application performance monitoring, log management, digital experience monitoring, continuous profiler, database monitoring, network monitoring, incident management, observability pipelines, cloud cost management, universal service monitoring, cloud security management, application security management. cloud SIEM, sensitive data scanner, and CI Visibility. The company was incorporated in 2010 and is headquartered in New York, New York.
NASDAQ ended the session with Datadog falling 17.09% to $88.14 on Tuesday while NASDAQ dropped 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Datadog has a trailing twelve months EPS of $-0.29.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.39%.
Sales Growth
Datadog’s sales growth is 23.3% for the current quarter and 29% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Datadog’s EBITDA is -2.8.
Revenue Growth
Year-on-year quarterly revenue growth grew by 32.7%, now sitting on 1.79B for the twelve trailing months.
More news about Datadog.
9. Redhill Biopharma Ltd. (RDHL) – -14.95%
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
NASDAQ ended the session with Redhill Biopharma Ltd. sliding 14.95% to $0.91 on Tuesday while NASDAQ slid 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Redhill Biopharma Ltd. has a trailing twelve months EPS of $-11.39.
Yearly Top and Bottom Value
Redhill Biopharma Ltd.’s stock is valued at $0.91 at 17:32 EST, under its 52-week low of $0.91.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Redhill Biopharma Ltd.’s EBITDA is 1.04.
Revenue Growth
Year-on-year quarterly revenue growth declined by 72.5%, now sitting on 52.3M for the twelve trailing months.
More news about Redhill Biopharma Ltd..
10. Five9 (FIVN) – -14.38%
Five9, Inc., together with its subsidiaries, provides intelligent cloud software for contact centers in the United States and internationally. The company offers virtual contact center cloud platform that delivers a suite of applications, which enables the breadth of contact center-related customer service, sales, and marketing functions. Its platform allows to manage and optimize customer interactions across voice, chat, email, web, social media, and mobile channels directly or through its application programming interfaces. The company serves customers in various industries, such as banking and financial services, business process outsourcers, retail, healthcare, technology, and education. Five9, Inc. was incorporated in 2001 and is headquartered in San Ramon, California.
NASDAQ ended the session with Five9 falling 14.38% to $69.92 on Tuesday while NASDAQ fell 0.79% to $13,884.32.
Earnings Per Share
As for profitability, Five9 has a trailing twelve months EPS of $-1.22.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.72%.
Yearly Top and Bottom Value
Five9’s stock is valued at $69.92 at 17:32 EST, way under its 52-week high of $120.39 and way above its 52-week low of $46.61.
Previous days news about Five9
- Five9 (fivn) Q2 earnings and revenues beat estimates. According to Zacks on Monday, 7 August, "While Five9 has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about Five9.
Stay up to date with our winners and losers daily report
